229 related articles for article (PubMed ID: 31421692)
21. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.
Yang Z; Yu L; Wang Z
Chin J Cancer Res; 2016 Feb; 28(1):65-71. PubMed ID: 27041928
[TBL] [Abstract][Full Text] [Related]
22. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
23. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
24. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
25. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
26. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
27. Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.
Jin W; Fei X; Wang X; Song Y; Chen F
Mediators Inflamm; 2020; 2020():8730608. PubMed ID: 32454797
[TBL] [Abstract][Full Text] [Related]
28. Novel Diagnostic Biomarkers of Prostate Cancer: An Update.
Anceschi U; Tuderti G; Lugnani F; Biava PM; Malossini G; Luciani L; Cai T; Marsiliani D; Filianoti A; Mattevi D; Costantini M; Misuraca L; Simone G
Curr Med Chem; 2019; 26(6):1045-1058. PubMed ID: 30215331
[TBL] [Abstract][Full Text] [Related]
29. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
30. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
31. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
32. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
33. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
34. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
[TBL] [Abstract][Full Text] [Related]
35. New Molecular Markers for Prostate Cancer Diagnosis.
Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
[TBL] [Abstract][Full Text] [Related]
36. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
37. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
38. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
39. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
Stephan C; Rittenhouse H; Hu X; Cammann H; Jung K
EJIFCC; 2014 Apr; 25(1):55-78. PubMed ID: 27683457
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNAs in prostate cancer: Biological and clinical implications.
Das R; Feng FY; Selth LA
Mol Cell Endocrinol; 2019 Jan; 480():142-152. PubMed ID: 30391670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
